A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV
NCT ID: NCT06652958
Last Updated: 2025-08-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
102 participants
INTERVENTIONAL
2024-10-02
2027-02-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults
NCT05627258
A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants
NCT05291520
Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults
NCT01993706
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
NCT02165267
VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults
NCT03015181
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A, Cohort 1
Healthy adult participants receive a single dose of VH4527079 Dose 1 (lowest dose) by IV infusion.
VH4527079
VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.
Arm A, Cohort 2
Healthy adult participants receive a single dose of VH4527079 Dose 2 (low dose) by IV infusion.
VH4527079
VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.
Arm A, Cohort 3
Healthy adult participants receive a single dose of VH4527079 Dose 3 (mid-low dose) by IV infusion.
VH4527079
VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.
Arm A, Cohort 4
Healthy adult participants receive a single dose of VH4527079 Dose 4 (mid-high dose) by IV infusion.
VH4527079
VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.
Arm A, Cohort 5
Healthy adult participants receive a single dose of VH4527079 Dose 5 (high dose) by IV infusion.
VH4527079
VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.
Arm A, Cohort 6
Healthy adult participants receive a single dose of VH4527079 Dose 6 (max dose) by IV infusion.
VH4527079
VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.
Arm A, Cohort 7
Healthy adult participants receive a single dose of VH4527079 Dose 1 (lowest dose) by SC injection.
VH4527079
VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.
Arm B, Cohort 8
Healthy adult participants receive three doses of VH4527079 dose that is selected in Arm A, by IV infusion, separated by a time interval.
VH4527079
VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.
Arm B, Cohort 9
Participants with HIV receive three doses of VH4527079 dose that is selected in Arm A, by IV infusion, separated by a time interval.
VH4527079
VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VH4527079
VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants who are overtly healthy based on a medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
* Participants who are able to understand and comply with protocol requirements and timetables, instructions, and protocol-stated restrictions.
* • For Cohort 9 (PWH in Arm B), well controlled HIV on first-line INSTI-based oral antiretroviral therapy (ART) without history of virologic failure. HIV infection is documented by any licensed rapid HIV rest or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry.
* Body weight more than or equal to (\>=)50.0 kg for men and \>=45.0 kg for women and Body Mass Index (BMI) within the range 18.5 to 31.0 kg/m\^2.
* Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
\- Participants who are female at birth are eligible to participate if at least one of the following conditions applies: Not pregnant or breastfeeding and, at least, one of the following conditions apply:
* Is not a Participant of childbearing potential (POCBP). OR
* Is a POCBP and agrees to use a highly effective contraceptive method 3 weeks prior to the start of this study and during the study.
* Capable of giving signed informed consent.
* Willing to have samples stored for future research for participants in Arm B; Cohort 8 (Healthy Volunteers) and Cohort 9 (PWH in Arm B).
Exclusion Criteria
* Weight \>115.0 kg.
* Any medical condition that is not well controlled.
* Positive HIV testing for participants enrolled in Arm A, Arm B Cohort 8, and Arm C.
* Any history of a severe allergic reaction with generalized urticaria, angioedema or anaphylaxis within the 2 years prior to enrollment that has a reasonable risk of recurrence during the study.
* The participant has an underlying skin disease or disorder, piercing, or tattoos that would interfere with assessment of injection site reactions (ISRs).
* History of sensitivity to any of the study medications or their components or drugs of their class, or a history of drug or other allergy.
* Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions.
* Any condition which, may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to take oral medication.
* Unstable liver disease, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease).
* Known history of cirrhosis with or without viral hepatitis co-infection.
* History of clinically relevant hepatitis within last 6 months.
* For Cohort 9 (PWH in Arm B), untreated syphilis infection (i.e., positive syphilis testing at screening) without documentation of treatment. Participants who have successfully completed treatment at least 7 days previously are eligible if recruitment is open. Positive syphilis testing at screening for any other Cohort is exclusionary.
* Lymphoma, leukemia, or any malignancy (except for breast cancer) within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years.
* Participants who poses a significant suicidality risk.
* Any pre-existing physical or mental condition which, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
* Clinically significant cardiovascular disease, as defined by history/evidence of congestive heart failure, symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting surgery or percutaneous transluminal coronary angioplasty or any clinically significant cardiac disease.
* Medical history of cardiac arrhythmias or cardiac disease or a family or personal history of long QT syndrome or sudden cardiac death. Any significant arrhythmia or ECG finding which, will interfere with the safety for the individual participant.
* Exposure to an experimental drug, human blood product, anticoagulants, or experimental vaccine (which does not have emergency, conditional, or standard market authorization) within 30 days, or within 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of study intervention or plans to receive live vaccines during the study.
* Any previous use of HIV Pre-exposure prophylaxis (PrEP) or Post-exposure prophylaxis (PEP) in Arm A (Cohorts 1 through 7) or Arm B (Cohort 8 only), or Arm C (Cohorts 10-14) either oral or parenteral, is exclusionary.
* Any previous use of Neonatal Fc receptor blockers (e.g., efgartigimod alfa-fcab).
* The participant has ever received an investigational HIV vaccine.
* Any approved or experimental non-HIV vaccination (e.g., SARS-CoV-2, HBV, influenza, pneumococcal polysaccharide) received within 2 weeks prior to study enrollment (Day 0).
* Exposure to an experimental drug, human blood product, anticoagulants or vaccine (which does not have emergency, conditional, or standard market authorization) within 30 days, or within 5 half-lives of the test agents, or twice the duration of the biological effect of the test agents, whichever is longer, prior to the first dose of study treatment or plans to receive live vaccines during the study.
* Where participation in the study would result in donation of blood or blood products in excess of 500 mL within 56 days.
* Exposure to more than 4 new chemical entities or vaccines within 12 months prior to the first dosing day.
* Past or intended use of over-the-counter or prescription medication including herbal medications within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to dosing.
* Participants who require concomitant medications known to be associated with a prolonged QTc.
* Participants receiving any protocol-prohibited medication(s) and who are unwilling or unable to switch to an alternate medication.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ViiV Healthcare
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Las Vegas, Nevada, United States
GSK Investigational Site
Austin, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
221877
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.